Publication
Controlled Goods Data: Overview of the Regulatory Framework
The Controlled Goods Program (“CGP”) is Canada’s domestic industrial security program, which regulates the examination, possession, and transfer of controlled goods.
Proposed repeal and replacement of NI 43-101: Standards of Disclosure for Mineral Projects: Update
Author:
Canada | Publication | June 23, 2025
On June 12, the Canadian Securities Administrators published a proposed replacement of National Instrument 43-101 Standards of Disclosure for Mineral Projects and its related companion policy and form of technical report, along with a notice and request for comment and proposed consequential amendments to various instruments and forms (the Proposal). The Proposal is open for comment until October 10, 2025.
The Proposal is intended to update and enhance the CSA’s current mineral disclosure requirements to provide investors with more relevant and improved disclosure, while continuing to foster fair and efficient capital markets for mining issuers. The Proposal was originally issued informally before PDAC 2025 to allow industry participants an opportunity for discussion.
For a summary of the Proposal see our prior update here, and for the source documents see here.
Senior Associate
Email
pierre-olivier.valiquette@nortonrosefulbright.com
Partner, Canadian Co-Head of Responsible Business and Sustainability
Email
alison.babbitt@nortonrosefulbright.com
Senior Partner
Email
paul.fitzgerald@nortonrosefulbright.com
Partner
Email
kristopher.miks@nortonrosefulbright.com
Recent publications
Publication
Government of Alberta launches nuclear energy engagement
On August 25, 2025, the Government of Alberta publicly re-affirmed its interest in nuclear energy with the launch of its Nuclear Energy Engagement (the Engagement).
Publication
Health Canada’s proposal to streamline approvals may accelerate biosimilar patent litigation
Health Canada has proposed a major change to the regulation of biosimilar drugs that may accelerate biologic patent litigation in Canada. Following the lead of other jurisdictions, Health Canada has proposed that biosimilar manufacturers no longer be required to conduct phase 3 clinical trials to enter the Canadian market.
Subscribe and stay up to date with the latest legal news, information and events . . .